Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | ULK1 | O75385 | 5/20 | 0.57 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.54 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086370 | 1.00 | MAPK8 (0.61) | MAPK8ULK1PKMYT1METALK | |
| SCHEMBL30086246 | 0.92 | ULK1 (0.59) | MAPK8ULK1PKMYT1ALKPTK2 | |
| SCHEMBL23754825 | 0.92 | ULK1 (0.59) | MAPK8ULK1PKMYT1ALKPTK2 | |
| SCHEMBL30086288 | 0.90 | MAPK8 (0.58) | MAPK8ULK1PKMYT1METALK | |
| SCHEMBL23754901 | 0.90 | MAPK8 (0.58) | MAPK8ULK1PKMYT1METALK | |
| SCHEMBL23764852 | 0.89 | PTK2 (0.66) | MAPK8ULK1PKMYT1ALKPTK2 | |
| SCHEMBL23754918 | 0.89 | MAPK8 (0.57) | MAPK8ULK1PKMYT1METALK | |
| SCHEMBL30086216 | 0.89 | MAPK8 (0.57) | MAPK8ULK1PKMYT1METALK | |
| SCHEMBL17547512 | 0.89 | ALK (0.70) | MAPK8ULK1PKMYT1METALK | |
| SCHEMBL23754834 | 0.87 | ULK1 (0.63) | MAPK8ULK1PKMYT1ALKPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| CN-115515589-A | ULK1/2 inhibitors and methods of use thereof | 萨克生物研究学院 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021163629-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | MAPK8 1702/4885ULK1 2/4885PKMYT1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.